High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Lilly's Foundayo records $98M in Q2 sales, while rising prescriptions, broader access and global expansion set the stage for H2 growth
Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant moves first.
Plus: Eli Lilly alleges black market weight loss drug sellers; shippers don’t buy Trump’s Hormuz strait claims
Lilly is suing several US companies that are allegedly selling illegal versions of its weight loss candidate, retatrutide.
Revenue surged 48% on Mounjaro and Zepbound demand, with full-year guidance raised.
Novo Nordisk's CEO conceded Eli Lilly is gaining market share even as oral Wegovy hits record prescriptions and the stock keeps falling.
Wegovy pill upside has already played out, leaving the multiple at the European pharma average
Lilly is trying to protect an experimental obesity medicine from unauthorized sellers before regulators decide whether to approve it.
Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development support from Eli Lilly tied to the program. See our latest analysis for Absci. Absci’s recent early Phase 1 ABS-201 update and Eli Lilly’s US$40 million commitment arrive after a sharp run, with the share price delivering a 77.55% 90 day return and a 160.66% year to date share price return, alongside a very large 3 year total shareholder...
The company has referred more than 200 sellers and individuals to regulators.
NVO faces near-term pressure from flat Wegovy sales, pricing challenges and pipeline setbacks, but its broad cardiometabolic pipeline offers long-term potential.
PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.
Obesity-drug giant Eli Lilly stock is approaching a new buy point as the ongoing stock market rally strengthens.
Lilly said the products being sold on the black market are unverified, unapproved, and not worth the risk.
Eli Lilly has filed six new lawsuits against U.S. entities that it alleges are selling a version of the company’s investigational weight-loss drug on the black market.
Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.
SAN FRANCISCO, Aug 12 (Reuters) - Eli Lilly on Wednesday said it had filed six lawsuits against U. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide, escalating its campaign against unauthorized sellers before the medicine has won regulatory approval.
Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, its prolactin receptor antibody, and a US$40 million investment and development support from Eli Lilly that extend its cash runway into the second half of 2028. Next, we’ll examine how Eli...
Moby summary of Absci Corporation's Q2 2026 earnings call
Novo Nordisk is playing catch-up in the GLP-1 race.
Absci (NASDAQ:ABSI) outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis, while reporting a larger cash balance following a June equity offering and strategic investment from El
A new market could accelerate Lilly's oral obesity ambitions
SpaceX has attractive prospects, but the market has already factored that into its share price.
Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.
The U.K. becomes Lilly's first international market for the pill.
Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the stock well past current targets.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
